November 2024 in “Journal of Investigative Dermatology” Reducing neutrophils or inhibiting NETs improves wound healing in sickle cell disease.
December 2023 in “Revista Urología Colombiana / Colombian Urology Journal” This systematic review found that treatments for sickle cell disease-related priapism are clinically diverse, with etilefrine, pseudoephedrine/etilefrine-5 inhibitors, and finasteride appearing promising, but further research with robust study designs is needed to establish evidence-based practices.
This study suggests that individuals with severe sickle cell disease, indicated by higher hemoglobin S and ferritin levels, may have lower cortisol levels as shown by reduced hair cortisol content.
May 2024 in “Asian Journal of Medicine and Health” This study explored the relationship between BMI percentiles and clinical severity in pediatric patients with different hemoglobin genotypes, finding significant BMI differences and associations with pain frequency, particularly noting that patients with HbSS experienced more pain than those with HbSC.
February 2026 in “The Journal of Sexual Medicine” In this case report, goserelin, a GnRH agonist, was effective in managing stuttering priapism and improving erectile function in a patient with sickle cell disease, suggesting potential for last-line treatment.